Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020–2024

“…KRI used this as the basis for an SC model analysis that explored confidence about no circulation as a function of time since the last positive surveillance signal [ 45 ], which helped to support the New York State and national leaders feel more confident about the end of the outbreak. KRI also explored the trade-offs of different poliovirus vaccine options for outbreak response in IPV-using countries, such as the US 2022 cVDPV2 outbreak, and considered a hypothetical cVDPV1 outbreak to show differences between poliovirus types [ 46 ], which supported the 2023 US decisions to offer IPV to adults [ 179 ] and deliberations by the Advisory Committee on Immunization Practices (ACIP) about the potential use of OPV in the US for oSIAs at its February 2024 meeting. This study also included a systematic review of modeling studies that included IPV use in outbreak response [ 46 ].…”

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024

“…Changes to the recommendations for vaccines and related agents in the 2024 immunization schedule for children and adolescents aged ≤18 years include new or updated recommendations for influenza vaccine ( 3 ), pneumococcal vaccines ( 4 ), respiratory syncytial virus monoclonal antibody (RSV-mAb) ( 5 ), respiratory syncytial virus vaccines (RSV) ( 6 ), COVID-19 vaccines ( 7 ), inactivated poliovirus vaccine (IPV) ( 8 ), Mpox vaccine (Mpox) ( https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/04-MPOX-Rao-508.pdf ), and meningococcal serogroups A, B, C, W, Y vaccine (MenACWY-TT/MenB-FHbp) ( https://www.cdc.gov/vaccines/acip/recommendations.html ). Diphtheria and tetanus toxoid adsorbed vaccine (DT), 13-valent pneumococcal conjugate vaccine (PCV13), bivalent COVID-19 mRNA vaccines, and meningococcal serogroups A, C, W, Y polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D, Menactra) were deleted from all sections of the schedule, because these products are no longer distributed or recommended for use in children and adolescents in the United States.…”

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024

“…Vaccine-specific changes in the 2024 immunization schedule for adults aged ≥19 years include new and updated recommendations for respiratory syncytial virus vaccines (RSV) ( 3 ), influenza vaccines ( 4 ), COVID-19 vaccines ( 5 ), inactivated poliovirus vaccine (IPV) ( 6 ), Mpox vaccine (Mpox) ( https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/04-MPOX-Rao-508.pdf ), and meningococcal serogroups A, B, C, W, Y pentavalent vaccine (MenACWY-TT/MenB-FHbp) ( https://www.cdc.gov/vaccines/acip/recommendations.html ). Any reference to meningococcal serogroups A, C, W, Y polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D [Menactra]) was removed from the schedule because this product is no longer distributed in the United States.…”